Photoradiation therapy in advanced carcinoma of the trachea and bronchus.
Photoradiation therapy is a new technique being investigated for the treatment of solid malignant tumors. In this study, 17 patients with advanced, recurrent, biopsy-proven malignant lesions of the trachea or main-stem bronchus were treated by photoradiation therapy. Patients received hematoporphyrin derivative intravenously three days prior to light therapy. The light was delivered from a fiberoptic fiber attached to the output beam of a dye laser (633 +/- 3 nm). The fiber was passed through the large channel of a bronchoscope (Olympus BF 2T). Of the 17 patients, two had no measurable response to the photoradiation therapy, six had partial necrosis of the tumor, seven patients had a greater than 50 percent reduction in the intraluminal volume of tumor, and two were lost to follow-up. Survival ranged from 5 to 210 days (median survival, 40 days). Complications of the treatment were significant in this group of advanced-stage patients and included excessive secretions, fever, pneumonia, and abscess formation.
D000230:Adenocarcinoma / Q000628:therapy*; D001984:Bronchial Neoplasms / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D005260:Female; D005334:Fever / Q000209:etiology; D017324:Hematoporphyrin Derivative; D006415:Hematoporphyrins / Q000627:therapeutic use*; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D010789:Phototherapy / Q000009:adverse effects; D011014:Pneumonia / Q000209:etiology; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012131:Respiratory Insufficiency / Q000209:etiology; D014134:Tracheal Neoplasms / Q000628:therapy*
D006415:Hematoporphyrins; D011838:Radiation-Sensitizing Agents; D017324:Hematoporphyrin Derivative